A Phase 2 interventional study of dexamethasone and ranibizumab in Choroidal Neovascularization and Age-Related Maculopathy, sponsored by Allergan. Completed at 3 sites in 3 countries. Open to participants aged 50 Years and older. Per ClinicalTrials.gov, last updated 2012-09-03.
Sponsored by Allergan (part of AbbVie) · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 45 studies testing ranibizumab in Choroidal Neovascularization — none open to participants now, none under way, none of them phase 3. Ranibizumab · Choroidal Neovascularization.
Among the 45 studies testing ranibizumab in Choroidal Neovascularization, this one is the 29th largest by enrollment, is one of 5 that started in 2008, is one of 10 in phase 2, and was the 19th registered.
214 studies on the registry are indexed under Choroidal Neovascularization; 12 are open to participants now.
Browse Choroidal Neovascularization studies →None of the 45 studies testing ranibizumab in Choroidal Neovascularization is open now. The open studies under Choroidal Neovascularization, anywhere →
Ranibizumab: first FDA approval 2006 (LUCENTIS), first EMA approval 2007. What it is approved for, and how studies give it, is on its page →
Of the 6 Choroidal Neovascularization studies recruiting now, 4 set no upper age limit and none stop at 75 or younger; none take children under 18; none take healthy volunteers.
This study: 50 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
45 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 9 · Phase 2 15 · Phase 3 12 · Phase 4 12
First in 2005; this study’s year is marked. 5 started in 2008.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 44 is below the median of 56 across 160 interventional studies indexed under Choroidal Neovascularization.
Median enrollment 62 across the 45 interventional studies. Of the 44 that completed or were terminated, 23 (52%) have results posted.
This tab as a report to print or save as PDF → With an account.
23 of 45 have an industry lead sponsor. The 10 most frequent:
This study is registered under Allergan, one of the names counted as AbbVie. Under that name alone:
Allergan is the lead sponsor of 505 studies on the registry; none are open to participants now.
Of its 93 completed or terminated interventional studies of FDA-regulated products, 91 (98%) have results posted.
AbbVie has 6 studies filed under Choroidal Neovascularization — fewer than ten, so there is no comparison to draw.
None of the studies under way reaches primary completion within a year.
Among the 45 studies testing ranibizumab in Choroidal Neovascularization, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The study will evaluate the safety and efficacy of the intravitreal dexamethasone implant as adjunctive therapy to Anti-VEGF treatment in the study eye of treatment naïve subjects with choroidal neovascularization secondary to age-related macular degeneration. Subjects will be followed for 26 weeks.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
700 µg dexamethasone intravitreal injection at Day 1 in the study eye. Ranibizumab injection at Week 2 or 3 per specified criteria and starting at Week 4 at the investigator's discretion in the study eye.
Drug: dexamethasone · Biological: ranibizumab
700 µg dexamethasone intravitreal injection at Day 1 in the study eye.
Also known as: Posurdex
Ranibizumab injection at Week 2 or 3 per specified criteria and starting at Week 4 at the investigator's discretion in the study eye.
Also known as: Lucentis®
Change From Baseline in Central Retinal Thickness as Measured by Optical Coherence Tomography (OCT) at Week 4
Optical Coherence Tomography (OCT), a laser based non-invasive diagnostic system providing high-resolution imaging sections of the retina, was performed on the study eye after pupil dilation at baseline and Week 4.
Time frame: Baseline, Week 4
Change From Baseline in Best Corrected Visual Acuity (BCVA) at Week 26
BCVA is measured using an eye chart and is reported as the number of letters read correctly (ranging from 0 to 100 letters). The lower the number of letters read correctly on the eye chart, the worse the vision (or visual acuity). An increase in the number of letters read correctly means that vision has improved.
Time frame: Baseline, Week 26
Percentage of Participants With Fluorescein Leakage Improved, Unchanged and Worsened From Baseline as Assessed by Fluorescein Angiography at Week 26
Fluorescein angiography (FA) is a technique for examining the circulation of the retina (and detecting any leakage) using a dye-tracing method. Photographs are taken with a specialized low-power microscope with an attached camera designed to photograph the interior of the eye, including the retina and optic disc. FA at Week 26 was compared to FA at Baseline. The percentage of participants in each of the following categories is reported: Improved (Leakage area decreased \>=10%), Unchanged (Leakage area changed \< 10%) and Worsened (Leakage area increased \>=10%).
Time frame: Baseline, Week 26
| Milestone | 700 µg Dexamethasone + Ranibizumab |
|---|---|
| Started | 44 |
| Completed | 43 |
| Not completed | 1 |
Optical Coherence Tomography (OCT), a laser based non-invasive diagnostic system providing high-resolution imaging sections of the retina, was performed on the study eye after pupil dilation at baseline and Week 4.
| Microns | 700 µg Dexamethasone + Ranibizumab |
|---|---|
| Baseline | 360.9 ± 69.23 |
| Change from baseline at Week 4 | -62.0 ± 78.68 |
BCVA is measured using an eye chart and is reported as the number of letters read correctly (ranging from 0 to 100 letters). The lower the number of letters read correctly on the eye chart, the worse the vision (or visual acuity). An increase in the number of letters read correctly means that vision has improved.
| Number of letters | 700 µg Dexamethasone + Ranibizumab |
|---|---|
| Baseline | 46.5 ± 17.73 |
| Change from baseline at Week 26 | 4.5 ± 9.62 |
Fluorescein angiography (FA) is a technique for examining the circulation of the retina (and detecting any leakage) using a dye-tracing method. Photographs are taken with a specialized low-power microscope with an attached camera designed to photograph the interior of the eye, including the retina and optic disc. FA at Week 26 was compared to FA at Baseline. The percentage of participants in each of the following categories is reported: Improved (Leakage area decreased \>=10%), Unchanged (Leakage area changed \< 10%) and Worsened (Leakage area increased \>=10%).
| Percentage of participants | 700 µg Dexamethasone + Ranibizumab |
|---|---|
| Improved | 74.4 |
| Unchanged | 18.6 |
| Worsened | 7.0 |
Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| 700 µg Dexamethasone + Ranibizumab | — | 6/44 (13.6%) | 9/44 (20.5%) |
| Event | 700 µg Dexamethasone + Ranibizumab |
|---|---|
| AnaemiaBlood and lymphatic system disorders | 1/44 |
| Cardio-respiratory arrestCardiac disorders | 1/44 |
| Coronary artery diseaseCardiac disorders | 1/44 |
| EndophthalmitisInfections and infestations | 1/44 |
| FallInjury, poisoning and procedural complications | 1/44 |
| GastroenteritisInfections and infestations | 1/44 |
| Pneumonia aspirationRespiratory, thoracic and mediastinal disorders | 1/44 |
| Urinary tract infectionInfections and infestations | 1/44 |
| Event | 700 µg Dexamethasone + Ranibizumab |
|---|---|
| Conjunctival haemorrhageEye disorders | 6/44 |
| Intraocular pressure increasedInvestigations | 3/44 |
| Age Continuous(Years) | 700 µg Dexamethasone + Ranibizumab |
|---|---|
| Mean | 72.3 ± 10.43 |
| Sex: Female, Male(Participants) | 700 µg Dexamethasone + Ranibizumab |
|---|---|
| Female | 25 |
| Male | 19 |
The record gives a start of Nov 2008, a primary completion of Nov 2009 and a completion of Apr 2010. It does not say whether these dates are actual or estimated.
Results were first posted in Sep 2012, 2 years 10 months after primary completion. A results delay was requested in Sep 2010.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Aug 2012. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Dexamethasone · Ranibizumab
Choroidal Neovascularization →